A single-cell map of patients with non-small cell lung cancer harboring rare-driver mutations after anti-PD-1 treatment
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Rui Fu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 72 Literaturangaben.
Abstract (Originalsprache)
The effects of the tumor microenvironment the therapeutic efficacy of combining chemotherapy with checkpoint inhibitors in patients with lung cancer harboring rare -driver mutations remain unclear. We utilized single-cell RNA- and T-cell receptor (TCR) -sequencing to explore the immune and stromal cell profiles of 12 tumors and five tumor-adjacent tissues in seven patients with non-small cell lung cancer (NSCLCs) with rare -driver mutations treated with anti-PD-1 agents combined with chemotherapy. A class of highly expanded T -cells, known as GZMK + CD8+ effector memory T cells (GZMK + CD8+Tem), was enriched in both responsive tumors with and without rare driver mutations, suggesting similar anti-tumor immune mechanisms in both cohorts and that high levels of GZMK + CD8+Tem might be associated with effective responses to combination therapy. Non-responsive tumors exhibited a highly immunosuppressive M2-phenotype with enriched macrophages and monocytes. In non-major pathological response tumors, tumor cells interacted with alveolar and M0 macrophages via LAMC2-(ITGA6+ITGB1), possibly leading to M2 polarization. OAS1 was specifically expressed in CHIT1+ and FABP4+ macrophages and promoted macrophage polarization. These findings suggest that combination therapy reprogramed alveolar and M0-like macrophages to a pro-tumor phenotype, creating an immunosuppressive tumor microenvironment that resisted anti-PD1 therapy. In conclusion, GZMK + CD8+Tem is crucial for effective responses, whereas myeloid cells contribute to the immunosuppressive effects in anti-PD-1 therapies for NSCLCs with rare-driver mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University,…
- Geneplus-Beijing Institute, Beijing, China.
Zitieren
APA
Fu, R., Zhang, C., Song, M. M., Gao, X., Li, F., Cai, M., Jiang, B. Y., Yang, X. N., Wu, Y. L., & Zhong, W. Z. (2025). A single-cell map of patients with non-small cell lung cancer harboring rare-driver mutations after anti-PD-1 treatment. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217595
Vancouver
Fu R, Zhang C, Song MM, Gao X, Li F, Cai M, et al. A single-cell map of patients with non-small cell lung cancer harboring rare-driver mutations after anti-PD-1 treatment. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217595
BibTeX
@article{Fu2025,
author = {Fu, Rui and Zhang, Chao and Song, Meng-Meng and Gao, Xuan and Li, Fang and Cai, Miao and Jiang, Ben-Yuan and Yang, Xue-Ning and Wu, Yi-Long and Zhong, Wen-Zhao},
title = {A single-cell map of patients with non-small cell lung cancer harboring rare-driver mutations after anti-PD-1 treatment},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217595}
}
EUVIMED